Fortis Healthcare

Fortis Healthcare Limited is an Indian for-profit private healthcare company headquartered in Gurgaon, Haryana. Its principal business is the operation and management of hospitals and related healthcare facilities, with services spanning multispecialty treatment, specialist medical care, diagnostics, and day-care services. The company is associated with a network of hospitals in India and has also operated healthcare facilities in Nepal, Dubai, and Sri Lanka. Fortis originated as a healthcare offshoot of Ranbaxy Laboratories. Its early operations were based in Mohali, Punjab, where the group established its first hospital. The company subsequently expanded through acquisitions, including the healthcare division of Escorts Group and the Escorts Heart and Research Center in Okhla, Delhi. This expansion helped establish Fortis as a significant participant in India's organized private hospital sector, particularly in cardiac and multispecialty care. The company underwent a major ownership and governance transition in 2018. Founders Malvinder Singh and Shivinder Singh resigned from the Fortis board amid allegations that money had been siphoned from the company. The episode occurred alongside legal proceedings involving the sale of Ranbaxy Laboratories to Daiichi Sankyo and materially affected the Singh brothers' ability to control Fortis. During the same period, Fortis attracted competing acquisition proposals, including an offer associated with Manipal Hospitals and TPG Capital. IHH Healthcare ultimately acquired a 31.1 percent controlling stake for approximately ₹4,000 crore and appointed representatives to the Fortis board. The proposed tender offer for a further 26 percent of Fortis from public shareholders was later halted after the Supreme Court directed that the status quo be maintained in connection with Daiichi Sankyo's contempt proceedings against the Singh brothers. Fortis nevertheless continued to expand its healthcare platform. In 2019, it announced the acquisition of assets associated with RHT Health Trust for an enterprise value of ₹4,650 crore. In 2023, it completed the acquisition of Medeor Hospital in Manesar from VPS Healthcare. In 2024, Fortis announced plans to acquire a 31 percent stake held by private-equity investors in its diagnostics subsidiary, Agilus Diagnostics, for ₹1,780 crore. Fortis Memorial Research Institute in Gurgaon serves as the company's headquarters facility. The network includes hospitals in the Delhi National Capital Region, including facilities in Faridabad, Noida, Vasant Kunj, and Shalimar Bagh, as well as hospitals and healthcare operations elsewhere in India and in selected overseas markets. The Wikipedia reference describes the company as managing 36 healthcare facilities. Fortis's positioning is that of a large, branded private healthcare provider offering specialist and multispecialty care rather than a single-specialty clinic or standalone diagnostics brand.

Fortis Healthcare was established in 1996 as a healthcare venture spun out of Ranbaxy Laboratories. Its first hospital was established in Mohali, Punjab, providing the foundation for a broader private hospital network. The company's early development reflected the growth of organized private healthcare in India, where branded hospital operators began assembling multispecialty facilities and specialist centers alongside traditionally fragmented medical provision. Fortis expanded beyond its initial Punjab base through acquisitions. A significant step was the purchase of the healthcare division of Escorts Group, including the Escorts Heart and Research Center in Okhla, Delhi. This transaction strengthened the company's presence in the National Capital Region and added established cardiac-care capabilities to its hospital portfolio. Fortis subsequently developed and managed facilities in Delhi NCR and other parts of India, while also maintaining operations in selected overseas markets, including Nepal, Dubai, and Sri Lanka. The company's ownership and governance structure became the subject of intense scrutiny in 2018. Founders Malvinder Singh and Shivinder Singh left the Fortis board after allegations that approximately $78 million had been diverted from the company. The dispute was linked to wider legal and financial issues surrounding the Singh family's business interests. In January 2018, the Delhi High Court upheld a 2016 Singapore arbitration ruling requiring the Singh brothers to pay Daiichi Sankyo ₹3,500 crore in damages, or approximately $550 million, over alleged misrepresentation in the sale of Ranbaxy Laboratories. The pressure on the founders led to a competitive process for Fortis. Manipal Hospitals and TPG Capital made a proposal to acquire the Singh brothers' interest for ₹3,900 crore. Following a bidding contest, IHH Healthcare completed the purchase of a 31.1 percent controlling interest for ₹4,000 crore. IHH representatives joined the Fortis board, marking a decisive shift from founder control to ownership by a major international healthcare group. A proposed tender offer for an additional 26 percent held by public shareholders was subsequently suspended after the Supreme Court ordered that the status quo be preserved in connection with Daiichi Sankyo's contempt proceedings against the Singh brothers. Following the ownership transition, Fortis continued to pursue expansion and portfolio development. In 2019, it announced the acquisition of RHT Health Trust assets for an enterprise value of ₹4,650 crore. In August 2023, the company completed the purchase of Medeor Hospital in Manesar from VPS Healthcare for approximately $27.23 million. In 2024, Fortis announced a plan to acquire a 31 percent stake held by private-equity firms in Agilus Diagnostics for ₹1,780 crore, reinforcing the relationship between its hospital operations and diagnostics business. Fortis Memorial Research Institute in Gurgaon serves as the company's headquarters facility. The network includes facilities in Delhi NCR locations such as Faridabad, Noida, Vasant Kunj, and Shalimar Bagh, in addition to hospitals elsewhere in India and operations in overseas markets. The reference material describes Fortis as managing 36 healthcare facilities. Its historical trajectory therefore combines organic hospital development, acquisition-led expansion, a major governance crisis, transition to IHH control, and continuing investment in hospitals and diagnostics.

1. 2024Agilus Diagnostics stake acquisition announced

   Fortis announces a plan to acquire a 31 percent stake in Agilus Diagnostics held by private-equity firms.

   Source
2. 2023Medeor Hospital acquisition completed

   Fortis completes the acquisition of Medeor Hospital in Manesar from VPS Healthcare.

   Source
3. 2019RHT Health Trust asset acquisition announced

   Fortis announces the acquisition of RHT Health Trust assets for an enterprise value of ₹4,650 crore.

   Source
4. 2018Founders leave the board

   Malvinder Singh and Shivinder Singh resign from the Fortis board amid allegations concerning the diversion of company funds.

   Source
5. 2018IHH Healthcare gains control

   IHH Healthcare completes the acquisition of a 31.1 percent controlling stake in Fortis.

   Source
6. 1996Fortis is established as a Ranbaxy healthcare offshoot

   Fortis Healthcare begins as a healthcare venture associated with Ranbaxy Laboratories.

   Source
7. 1996First hospital opens in Mohali

   The company establishes its first hospital in Mohali, Punjab.

   Source

A large, branded private healthcare network focused on multispecialty hospitals, specialist treatment, diagnostics, and organized healthcare delivery in India and selected overseas markets.

• Multispecialty hospital servicesHospital care

  Fortis's core offering is hospital-based multispecialty care. Its facilities provide coordinated treatment across multiple medical disciplines, allowing the brand to serve patients requiring routine interventions, complex procedures, inpatient care, and specialist consultations. The network includes hospitals in Delhi NCR and other Indian locations, as well as facilities in selected overseas markets.

• Cardiac careSpecialist care

  Cardiology and cardiac treatment are important parts of Fortis's clinical portfolio. The company's acquisition of the Escorts healthcare division, including the Escorts Heart and Research Center in Okhla, added established heart-care capabilities to its network and supported Fortis's development as a multispecialty hospital operator.

• OrthopaedicsSpecialist care

  Orthopaedic services are among the specialist offerings associated with Fortis hospitals. They form part of the broader clinical model in which the company combines specialist departments with inpatient, surgical, and multispecialty hospital infrastructure.

• Neurology and neurosciencesSpecialist care

  Fortis hospitals include neurological and neurosciences care within their specialist service mix. These services sit alongside cardiac, orthopaedic, and other disciplines within the network's multispecialty model.

• Agilus DiagnosticsDiagnostics

  Agilus Diagnostics is Fortis's diagnostics subsidiary. In 2024, Fortis announced a plan to acquire a 31 percent stake held by private-equity firms, indicating an effort to strengthen its participation in diagnostic services alongside hospital operations.

• Day-care healthcare servicesAmbulatory care

  Day-care services are part of the healthcare formats associated with the Fortis network. They complement full-service hospitals by supporting treatments and procedures that do not require an overnight inpatient stay.

• 2024Planned acquisition of an Agilus Diagnostics stakeM&A

  Fortis sought to deepen its ownership of its diagnostics subsidiary and strengthen the connection between hospital and diagnostic services.

  What changed. Fortis announced that it would acquire a 31 percent stake in Agilus Diagnostics held by private-equity firms for ₹1,780 crore.

  Aftermath. The announced transaction would increase Fortis's ownership exposure to Agilus Diagnostics.

  Proposed acquisition consideration. ₹1,780 crore for a 31% stake (2024)

  Source
• 2023Acquisition of Medeor Hospital in ManesarM&A

  Fortis continued to expand its hospital network after IHH Healthcare became its controlling shareholder.

  What changed. Fortis completed the acquisition of Medeor Hospital in Manesar from VPS Healthcare.

  Aftermath. The acquisition added a Manesar hospital to Fortis's Indian network.

  Acquisition price. $27.23 million (August 2023)

  Source
• 2019Acquisition of RHT Health Trust assetsM&A

  Fortis pursued expansion of its healthcare asset base after the change in ownership.

  What changed. The company announced the acquisition of RHT Health Trust assets at an enterprise value of ₹4,650 crore.

  Aftermath. The transaction expanded Fortis's healthcare asset portfolio.

  Enterprise value. ₹4,650 crore (2019)

  Source
• 2018Selection of IHH Healthcare as controlling investorM&A

  Fortis faced a competitive acquisition process after the Singh brothers came under financial and legal pressure and resigned from the board.

  What changed. Following competing proposals, IHH Healthcare completed the acquisition of a 31.1 percent controlling stake for ₹4,000 crore and appointed representatives to the Fortis board.

  Aftermath. The transaction shifted Fortis from founder-associated control to control by IHH Healthcare. A proposed tender offer for an additional 26 percent was later halted following a Supreme Court status-quo order.

  Acquisition consideration. ₹4,000 crore for a 31.1% controlling stake (2018)

  • Manipal Hospitals and TPG Capital — They had previously submitted a competing proposal to acquire the Singh brothers' stake.
  Source

• 2018Allegations involving the Singh brothers and Fortis fundsControversy

  Fortis founders Malvinder Singh and Shivinder Singh resigned from the board after allegations that approximately $78 million had been siphoned from the company. The episode contributed to a governance crisis and preceded the change in control to IHH Healthcare.

  Source
• 2018Daiichi Sankyo dispute and Fortis stake-sale proceedingsControversy

  The Delhi High Court upheld a Singapore arbitration ruling requiring the Singh brothers to pay Daiichi Sankyo ₹3,500 crore in damages over alleged misrepresentation in the Ranbaxy sale. Daiichi Sankyo later pursued contempt proceedings, and the Supreme Court's status-quo order affected the proposed tender offer for additional Fortis shares.

  Source

• 2024Fortis announces planned purchase of a stake in Agilus Diagnostics

  Fortis announced that it would acquire a 31 percent stake held by private-equity firms in its diagnostics subsidiary, Agilus Diagnostics, for ₹1,780 crore.

  M&A
  Source
• 2023Fortis completes acquisition of Medeor Hospital in Manesar

  Fortis completed its acquisition of Medeor Hospital in Manesar from VPS Healthcare for approximately $27.23 million.

  M&A
  Source
• 2019Fortis announces acquisition of RHT Health Trust assets

  Fortis announced the acquisition of RHT Health Trust assets at an enterprise value of ₹4,650 crore.

  M&A
  Source
• 2018Competing bids emerge for control of Fortis Healthcare

  Manipal Hospitals and TPG Capital offered to acquire the Singh brothers' stake in Fortis during a contested sale process.

  M&A
  Source
• 2018IHH Healthcare acquires a controlling stake in Fortis

  After a bidding process, IHH Healthcare completed the acquisition of a 31.1 percent controlling stake in Fortis and appointed representatives to the board.

  M&ALeadership change
  Source

1. Fortis Healthcare
2. Fortis Healthcare official website